The Effects of L-Asparaginase on Blood Triglycerides, Glucose, and Albumin Levels and Coagulation State in ALL Patients in Pediatric Ward
,
Abstract
Asparaginase is one of the most important agents in the treatment of ALL. However, it has some side effects including dislipidemia, hyperglycemia, coagulopathy and hepatotoxicity. We studied its side ef-fects on our patients. The effects of L-asparaginase were assessed on 25 new ALL patients (case group) and 25 patients with known ALL who had completed their treatment before. Sixty two percent of cases were male and remainder was female. The mean age of patients was 7.2 ± 3.8 years. In our patients, there was a rise in triglycerides (TG) was seen following L- asparaginase administration (P = 0.02). Also, PT prolongation (P = 0.02) and hypoalbominemia (P = 0.002) were detected which could PT prolongation and hypoalbuminemia may be seen with L-asparaginase therapy that can be prevented with transfusion of FFP. Hypertriglyceridemia is often asymptomatic with no need for therapy.
Capizzi RL. Asparaginase revisited. Leuk Lymphoma 1993; (10 Suppl): 147-50.
Ettinger LJ, Ettinger AG, Avramis VI, Gaynon PS. Acute lymphoblastic leukemia: A guide to asparaginase and pegaspargase therapy. Biodrugs 1997; 7: 30-9.
Cario MS. Adverse reactions of L-asparaginase. Am J Pediatr Hematol Oncol 1982; 4(3): 335-9.
Pui CH, Chesney CM, Weed J, Jackson CW. Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol 1985; 3(9): 1266-72.
Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving Lasparaginase and prednisone. J Pediatr 1981; 99(1): 46-50.
Parsons SK, Skapek SX, Neufeld EJ, Kuhlman C, Young ML, Donnelly M, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997; 89(6): 1886-95.
Zalewska-Szewczyk B, Przybysz K, Kowalewska-Pietrzak M, Stolarska M, Bodalski J. Iatrogenic hyperlipidemia after l-asparaginase and glucocorticoid treatment in two children with acute lymphoblastic leukemi. Pol Merkur Lekarski 2003; 15(87): 256-8.
Hoogerbrugge N, Jansen H, Hoogerbrugge PM. Transient hyperlipidemia during treatment of ALL with Lasparaginase is related to decreased lipoprotein lipase activity. Leukemia 1997; 11(8): 1377-9.
Ridola V, Buonuomo PS, Maurizi P, Putzulu R, AnnunziataML, Pietrini D, et al. Severe acute hypertriglyceridemia during acute lymphoblastic leukemia induction successfully treated with plasmapheresis. Pediatr Blood Cancer 2008; 50(2): 378-80.
Miniero R, Saracco P, Einaudi S, Garofalo F, Lange MM, Madon E. L-asparaginase-induced coagulopathy in children with acute lymphoblastic leukaemia. Drugs Exp Clin Res1987; 13(6): 377-9.
Sutor AH, Niemeyer C, Sauter S, Witt I, Kaufmehl K, Rombach A,et al. Changes in blood coagulation in treatment with ALL-BFM-90 and NHL-BFM-90 protocols. Klin Padiatr 1992; 204(4): 264-73.
Attarbaschi A, Mann G, Kronberger M, Witt V, Gadner H, Dworzak M. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000. Klin Padiatr 2003; 215(6): 321-6.
Hsu YJ, Chen YC, Ho CL, Kao WY, Chao TY. Diabetic ketoacidosis and persistent hyperglycemia as long-term complications of L-asparaginase-induced pancreatitis. Zhonghua Yi Xue Za Zhi (Taipei) 2002; 65(9): 441-5.
Iyer RS, Rao SR, Pai S, Advani SH, Magrath IT. Lasparaginase related hyperglycemia. Indian J Cancer 1993; 30(2): 72-6.
Ettinger LJ, Lerner ED, Manglani MV. Toxicity study of pegaspargase. Indian Pediatr 2000; 37(6): 631-6.
| Files | ||
| Issue | Vol 47, No 4 (2009) | |
| Section | Articles | |
| Keywords | ||
| L-asparaginase ALL hyperlipidemia hyperglycemia | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
